Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?

Autor: Van der Schueren BJ, Lunnon MW, Laurijssens BE, Guillard F, Palmer J, Van Hecken A, Depré M, Vanmolkot FH, de Hoon JN

Publikováno v: Journal of Clinical Pharmacology; Mar2009, Vol. 49 Issue 3, p281-290, 10p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug-drug interactions.

Autor: Armani S; CRS Clinical Research Services, Mannheim, Germany., Geier A; Department of Internal Medicine and Hepatology, University Hospital, Würzburg, Germany., Forst T; CRS Clinical Research Services, Mannheim, Germany., Merle U; Department of Internal Medicine IV, University Hospital, Heidelberg, Germany., Alpers DH; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA., Lunnon MW; Rickmansworth, Hertfordshire, UK.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Apr; Vol. 90 (4), pp. 942-958. Date of Electronic Publication: 2024 Jan 25.

Prolonged pharmacodynamic effects of S-0139, an intravenously administered endothelin A (ET) antagonist, in the human forearm blood flow model.

Autor: Lunnon MW; Discovery Medicine, GSK R&D, Harlow, UK., Wallace SM, Palmer JE, Francis-Lang A, Laurijssens BE, Mistry P, Albala B, Nagafuji T, Wilkinson IB, Maltby K

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2010 Mar; Vol. 69 (3), pp. 252-61.